500 | Spyglass Pharma

top of page

About Us
Our Technology
Pipeline
For Patients
More

Use tab to navigate through the menu items.

Time Out

This page isn’t available right now. But we’re working on a fix, ASAP. Try again soon.

SpyGlass Pharma™ Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma

ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, held from April 5-8 in Boston. (View full press release)

Tel: 949-284-6904

27061 Aliso Creek Rd, Suite 100
Aliso Viejo, CA 92656

SUBSCRIBE

Sign up to receive SpyGlass Pharma™ news and updates.

Email

Thanks for submitting!

© 2024 SpyGlass Pharma™. All Rights Reserved.

Follow us on LinkedIn

bottom of page